Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 15, 2026
Daily News
January 15, 2026
- Takeda to Halt Sales of Cell Therapy Alofisel in Japan
January 15, 2026
- Japan Sets New Pricing Rules for Conditionally Approved Regenerative Medicines, Starting with Elevidys
January 15, 2026
- Rohto to Roll Out 3- or 4-Day Workweek Option from April to Spur Growth, Retention
January 15, 2026
- Rakuten Joins Hands with LOTTE Biologics to Boost Production for Photoimmunotherapy
January 15, 2026
- Japan’s Maternal RSV Vaccine Uptake at 11.6%, Survey Finds
January 15, 2026
- Daiichi Sankyo Unveils Brand Site for OTC NorLevo Ahead of Launch
January 15, 2026
- Cheplapharm to Take Over Japan MA for UCB’s Myocalm
January 15, 2026
- Meiji-Daito Generic Consortium Expands to Eight Members
January 15, 2026
- Daiichi Launches PIII Datroway Trial in TROP2 Positive NSCLC
January 15, 2026
- Opdivo-Yervoy Combo Expands Label for Colorectal Cancer in Taiwan: Ono
January 15, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…